Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Ibrutinib, a Brutonâ€™s tyrosine kinase (BTK) inhibitor, is a novel anticancer drug used for treating several types of cancers. In this study, we aimed to determine the role of ibrutinib on GBM.